A panel of top radiation oncologists in the US and the UK has addressed the question of putting off or shortening various kinds of radiation treatment (RT) for prostate cancer at a time when it is best to maintain distance from institutions that treat patients.
Their recommendations depended on the disease setting. For detailed recommendations, see this table. They recommend that:
Consultations and return visits post-RT should be handled by telephone or online if possible.
The preferred therapy for all favorable-risk prostate cancers (very low-, low-, and favorable intermediate-risk) is active surveillance during the pandemic.
4-month or 6-month depot injections of an LHRH agonist (e.g., Lupron, Eligard, Zoladex, etc.) should be used prior to primary RT for all unfavorable-risk patients (unfavorable intermediate-risk, high-risk, and lymph node positive). If there must be treatment during the pandemic, a shortened course of external beam RT using moderate (20 treatments) or extreme hypofractionation (five treatments) is recommended.
Brachytherapy should be avoided during the pandemic, and delayed until afterwards if desired, due to high exposure of anesthesiological medical staff.
Adjuvant/salvage RT should be delayed. 4-month or 6-month depot injections of an LHRH agonist (e.g., Lupron, Eligard, Zoladex, etc.) may be used during the delay.
De-bulking the prostate with RT in patients with low volume metastases can be delayed with 4-month or 6-month depot injections of an LHRH agonist (e.g., Lupron, Eligard, Zoladex, etc.).
Treatment of oligometastases with one to three RT treatments may be delayed with 4-month or 6-month depot injections of an LHRH agonist (e.g., Lupron, Eligard, Zoladex, etc.).
